Biostock summary of 2023: “Chordate continues its marketing activities and exit strategy”

In a new article, Biostock summarizes Chordate Medical’s 2023 and interviews CEO Anders Weilandt about the focus and goals for 2024.

“First and foremost, we aim to achieve product registration for both indications in the United Arab Emirates and for migraine in Saudi Arabia. The Chinese registration project is expected to meet its targets for the period, and work on obtaining market clearance in the USA will continue […] Furthermore, the year is entirely focused on generating more sales and gradually initiating more clinics, primarily for the migraine indication but also for rhinitis – where we have the potential to make headway in securing deals”, says Anders Weilandt to Biostock.

Read the full article

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy